Citations

Clear

5626 citation(s) found for "Anderson, KS".

Comparative outcomes of arteriovenous malformations treatment in eloquent versus non-eloquent brain: A multicenter study with propensity-score weighting
Adeeb, Nimer , Abdalrazeq, Hammam , Salim, Hamza , Aslan, Assala , Tjoumakaris, Stavropoula I, Ogilvy, Christopher S. , Başkaya, Mustafa K. , Kondziolka, Douglas, Sheehan, Jason P. , Riina, Howard A. , Abushehab, Abdallah, Naamani, Kareem El, Ironside, Natasha , Gummadi, Sanjeev, Ataoglu, Cagdas , Keleş, Abdullah , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Park, Min S. , Erginoğlu, Ufuk , Sen, Rajeev , Griessenaur, Christoph, Burkhardt, Jan‐Karl , Starke, Robert M., Sekhar, Laligam N., Altschul, David , Haranhalli, Neil , McAvoy, Malia , Zeineddine, Hussein A. , Abla, Adib A. , Atallah, Elias , Rosenwasser, Robert H. , Stapleton, Christopher J. , Koch, Matthew, Srinivasan, Visish M. , Bulsara, Ketan R., Kim, Louis J. , Pukenas, Bryan , Smith, Edward R. , Alaraj, Ali , Patel, Aman B. , Notarianni, Christina , Lawton, Michael T. , Guthikonda, Bharat , Salim, Hamza , Dmytriw, Adam A , Levitt, Michael R , Chen, Peng R , Alaraj, Ali , Guthikonda, Bharat , Jabbour, Pascal , Abla, Adib , Altschul, David J , Ogilvy, Christopher S , Alwakaa, Omar , Keles, Abdullah , Erginoglu, Ufuk , Smith, Edward , Burkhardt, Jan‐Karl , Musmar, Basel , Roy, Joanna M. , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Dmytriw, Adam A. , Naamani, Kareem El , Abdelsalam, Ahmed , Kumbhare, Deepak , Essibayi, Muhammed Amir , Tos, Salem M , Mantziaris, Georgios , Hanalıoğlu, Şahin , Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Sekhar, Laligam N. , Levitt, Michael R. , Gooch, Michael Reid , Koch, Matthew J. , Blackburn, Spiros , Kim, Louis J. , Choudhri, Omar , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Savardekar, Amey Rajan , Cuellar, Hugo , Morcos, Jacques J. , Jabbour, Pascal

Mayo Clinic

International Journal of Stroke | February 14, 2025 | Volume: 20 | Issue: 7 | Pages: 852-863

10.1177/17474930251323503 | PMID 39948730 Get It

Background: Arteriovenous malformations (AVMs) are complex vascular anomalies with a high risk of hemorrhage and neurological deficits, especially when located in eloquent brain regions. The eloquence of an AVM location is a critical factor in the treatment planning, influencing both the risk of complications and long-term functional outcomes. This study aims to compare outcomes between eloquent and non-eloquent AVMs. Methods: This multicenter, retrospective study utilized data from the Multicenter International Study for Treatment of Brain AVMs (MISTA) consortium. Patients with eloquent and non-eloquent AVMs were compared on baseline characteristics, angiographic outcomes, and functional outcomes using the modified Rankin Scale (mRS). Propensity score weighting (IPTW) was applied to adjust for confounding variables. Results: The study included 1013 patients, with 498 (49.2%) AVMs located in eloquent regions and 515 (50.8%) in non-eloquent regions. In unadjusted analysis, eloquent AVMs had lower complete obliteration rates (67.6% vs 79.5%, OR: 0.53, 95% CI: 0.39–0.72, p < 0.001) and higher complication rates (24.5% vs 19.0%, OR: 1.38, 95% CI: 1.02–1.86, p = 0.03) compared to non-eloquent AVMs. After IPTW adjustment, eloquent AVMs continued to show significantly higher odds of overall complications (OR: 1.68, 95% CI: 1.12–2.52, p = 0.01) and symptomatic complications (OR: 1.77, 95% CI: 1.12–2.80, p = 0.01). Secondary analysis within the eloquent group indicated that embolization was linked to an elevated risk of complications. Surgery and radiosurgery showed comparable functional outcomes at last follow-up and complications rates with higher complete obliteration rates in surgery. Conclusion: AVMs in eloquent brain areas present higher risks of complications and lower obliteration rates, emphasizing the need for cautious, individualized treatment planning. Within the eloquent group, embolization increased the risk of complications, while surgery and radiosurgery showed comparable functional outcomes at last follow-up and complication rates with higher complete obliteration rates in surgery. These findings highlight the importance of location in AVM management and support further research focusing on comparing treatment strategies for AVMs in eloquent brain areas.
Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies
Locke, Frederick L. , Muñoz, Javier , Tees, Michael, Lekakis, Lazaros J. , Vos, Sven de , Nath, Rajneesh , Stevens, Don A., Malik, Shahbaz A. , Shouse, Geoffrey , Hamadani, Mehdi , Fisher, P.W. , Feng, Amy, Navale, Lynn, Gall, John B. Le , Neelapu, Sattva S. , Munoz, Javier L , Shouse, Geoffrey P , Oluwole, Olalekan O , Perales, Miguel-Angel , Miklos, David B , Fisher, Paul W , Le Gall, John B , Neelapu, Sattva S , Hamadani, Mehdi , Locke, Frederick L , Oluwole, Olalekan O. , Perales, Miguel‐Angel , Miklos, David B.

Mayo Clinic

Journal of Clinical Oncology | February 13, 2025 | Volume: 43 | Issue: 14 | Pages: 1695-1705

10.1200/jco-24-01933 | PMID 39946666 Get It

PURPOSE Off-the-shelf, allogeneic CD19 chimeric antigen receptor (CAR) T-cell products may improve access to treatment versus autologous ones. We report the phase I experience of the allogeneic CD19 CAR T-cell product cemacabtagene ansegedleucel (cema-cel) and its predecessor, ALLO-501, in CD19 CAR T-naïve patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). METHODS In the ALPHA2/ALPHA studies, the safety and efficacy of allogeneic CD19 CAR T cells were evaluated in CD19 CAR T treatment-naïve patients with R/R LBCL. Patients received healthy donor-derived, human leukocyte antigen–unmatched cema-cel/ALLO-501 following a 3-day lymphodepletion regimen of fludarabine (30 mg/m 2 once daily), cyclophosphamide (300 or 500 mg/m 2 once daily), and escalating doses of the anti-CD52 monoclonal antibody, ALLO-647. RESULTS As of September 26, 2024, 33 CD19 CAR T-naïve patients with LBCL (median age, 66 years; median number of previous therapies, 3) received allogeneic CAR T cells. CAR T-cell expansion was observed following infusion, with persistence observed up to 4 months. The overall and complete response (CR) rates were 58% and 42%, respectively; the median duration of response in patients with a CR was 23.1 months. The most common treatment-emergent adverse events were hematologic toxicities. No cases of graft-versus-host disease, immune effector cell–associated neurotoxicity syndrome, or grade ≥3 cytokine release syndrome were reported. CONCLUSION Allogeneic CD19 CAR T cells demonstrated promising overall and durable CR rates with a manageable safety profile in CD19 CAR T-naïve patients with R/R LBCL, supporting additional evaluation of cema-cel in patients with LBCL.
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
Chávez, Julio C. , Dickinson, Michael , Muñoz, Javier , Ulrickson, Matthew L. , Thiéblemont, Catherine , Oluwole, Olalekan O. , Herrera, Alex F. , Ujjani, Chaitra S. , Lin, Yi , Riedell, Peter A. , Kekre, Natasha , Vos, Sven de , Wulff, Jacob , Williams, Chad M. , Kloos, Ioana , Xu, Hairong , Neelapu, Sattva S. , Neelapu, Sattva S , Chavez, Julio C , Oluwole, Olalekan O , Dickinson, Michael , Munoz, Javier L , Riedell, Peter A , Winters, Joshua

Mayo Clinic

Blood | February 12, 2025 | Volume: 145 | Issue: 20 | Pages: 2303-2311

10.1182/blood.2024027347 | PMID 39938019 Get It

ZUMA-12 is a multicenter phase 2 study evaluating axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy as part of first-line treatment for high-risk large B-cell lymphoma (LBCL). In the primary efficacy analysis (n = 37; median follow-up, 15.9 months), axi-cel demonstrated a high rate of complete responses (CR; 78%) and a safety profile consistent with prior experience. Here, we assessed updated outcomes from ZUMA-12 in 40 treated patients after ≥3 years of follow-up. Eligible adults underwent leukapheresis, lymphodepleting chemotherapy, and axi-cel infusion (2 × 106 CAR T cells/kg). Investigator-assessed CR, objective response, survival, safety, and CAR T-cell expansion were assessed. The CR rate among response-evaluable patients (n = 37) increased after the primary analysis to 86% (95% confidence interval [CI], 71%-95%), with a 92% objective response rate. After a median follow-up of 47.0 months (range, 37.1-57.8 months), 36-month estimates (95% CI) of duration of response and event-free, progression-free, and overall survival were 81.8% (63.9%-91.4%), 73.0% (55.6%-84.4%), 75.1% (57.5%-86.2%), and 81.1% (64.4%-90.5%), respectively. In total, 4 patients had new malignancies, 2 occurring after the data cutoff of the primary analysis; none were axi-cel–related. Eight patients died on study, 2 of whom died from nonrelapse mortality causes. After long-term follow-up, axi-cel demonstrated a high durable response rate, with no new safety signals after the primary analysis, suggestive of an effective first-line therapy with curative intent in high-risk LBCL. Further assessments are needed to determine its benefit vs standard of care. This trial was registered at clinicaltrials.gov, as NCT03761056.
Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Inaba, Hiroto , Teachey, David T. , Annesley, Colleen , Batra, Sandeep , Beck, Jill C., Cooper, Stacy , Dallas, Mari , Oliveira, Satiro De , Kelly, Kara M. , Kohorst, Mira A. , Kutny, Matthew A. , Lee‐Miller, Cathy , Ludwig, Kathleen , Madden, Lisa, Maloney, Kelly W. , Massaro, Stephanie, Morocco, Perry , Muller, Brad, Murphy, Lindsey , Nardi, Valentina , Rossoff, Jenna , Schuettpelz, Laura G. , Sun, Jessica , Wong, Victor , Yanik, Gregory A. , Stehman, Katie, Inaba, Hiroto , Colace, Susan I. , Kitko, Carrie L. , Lacayo, Norman James , Mangum, David Spencer , McCall, David C. , Shah, Bijal , Awotiwon, Ajibola

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 12, 2025 | Volume: 23 | Issue: 2 | Pages: 41-62

10.6004/jnccn.2025.0006 | PMID 39938467 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Acute Lymphoblastic Leukemia (ALL) were developed as a result of meetings convened by a multidisciplinary panel of pediatric ALL experts, with the goal of providing recommendations on standard treatment approaches based on current evidence. The NCCN Guidelines for pediatric ALL focus on risk assessment and stratification of risk-adapted therapy; treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL; and supportive care considerations. This selection from the NCCN Guidelines for pediatric ALL focuses on the diagnosis of and management of pediatric T-ALL.
Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
Shi, Qian , Paiva, Bruno , Pederson, Levi , Dimier, Natalie , Talpes, Ela, Prior, Thomas J. , Órfão, Alberto , Sonneveld, Pieter , Kumar, Shaji , Patel, Reshma, Bartlett, Blake, Schecter, Jordan M. , Seckinger, Anja , D’Agostino, Mattia , Goldschmidt, Hartmut , Owen, Roger G., Durie, Brian G.M. , Munshi, Nikhil C. , Group, on behalf of the International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM), Pederson, Levi D , Moreau, Philippe , Sonneveld, Pieter , Kumar, Shaji K , Dixon, Jesse G. , McCarthy, Phillip , Hose, Dirk , Seckinger, Anja , Mattia, D'Agostino , Goldschmidt, Hartmut , Oliva, Stefania , Anderson, Kenneth C , San-Miguel, Jesus , Munshi, Nikhil C , Shi, Qian , Paiva, Bruno , Orfao, Alberto , Moreau, Philippe , Patel, Reshma, McCarthy, Philip L. , Hose, Dirk , Oliva, Stefania , Anderson, Kenneth C. , Miguel, Jesús F. San , Group, on behalf of the International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM)

Mayo Clinic

Journal of Clinical Oncology | February 12, 2025 | Volume: 43 | Issue: 11 | Pages: 1289-1301

10.1200/jco-24-02020 | PMID 39938021 Get It

PURPOSE Newly approved drugs and combinations treating multiple myeloma (MM) have resulted in substantial improvements in patients' survival. To deliver rapid access to newer therapies, an earlier end point to expedite clinical trials is needed. Our objective was to evaluate the minimal residual disease–negative complete response (MRD-CR) as an intermediate end point for progression-free survival (PFS) and overall survival (OS) in newly diagnosed (ND) transplant-eligible (NDTE) patients, ND transplant-ineligible (NDTinE) patients, and patients with relapsed/refractory (RR) MM. PATIENTS AND METHODS Individual patient data from 20 randomized multicenter trials were collected. Eleven studies (4,773 patients) with sufficient data were analyzed to evaluate whether 9- or 12-month MRD-CR classified at a 10 –5 threshold could be reasonably likely to predict the clinical benefit of new agents regarding PFS and OS. Global odds ratio (OR) was estimated using the bivariate Plackett Copula model. Supportive evaluation included correlations of the treatment effects on MRD-CR end points and PFS/OS, evaluated by both linear regression ( R 2 weighted least squared ) and Copula ( R 2 Copula ) models. RESULTS The analysis demonstrated that both 9- and 12-month MRD-CR strongly correlated with PFS at patient level in NDTE patients, NDTinE patients, and patients with RRMM. Global ORs ranged from 3.06 to 16.24, all with 95% CIs excluding 1.0. Encouraging trial-level correlations ( R 2 , 0.61-0.70) were observed by pooling three populations and were stronger ( R 2 , 0.67-0.78) in the ND population. Similar results were observed for OS. CONCLUSION Our findings provided the support for use of MRD-CR classified at a 10 –5 threshold at either 9 or 12 months after starting of the treatment, as an intermediate end point to support accelerated approvals, in future trials in NDTE patients, NDTinE patients, and patients with RRMM.
NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025
Pfister, David G. , Spencer, Sharon A., Adkins, Douglas, Birkeland, Andrew C. , Busse, Paul M., Durm, Greg Andrew , Fakhry, Carole , Galloway, Thomas J. , Geiger, J.L. , Gillison, Maura L. , Haddad, Robert I. , Hitchcock, Ying J. , Jimeno, Antonio , Leizman, Debra S., Maghami, Ellie, Mell, Loren K. , Pinto, Harlan A. , Price, Katharine A. , Rocco, James W. , Rodriguez, Cristina P. , Sher, David J. , Wang, He , Weinstein, Gregory S., Yom, Sue S. , Zhen, Weining, Darlow, Susan, Price, Katharine, Haddad, Robert , Yom, Sue S , Colevas, Alexander Dimitrios , Cmelak, Anthony J. , Adkins, Douglas, Brizel, David M. , Caudell, Jimmy J , Glastonbury, Christine M. , Hicks, Wesley L. , Juloori, Aditya , Kase, Michael, Mittal, Bharat B. , Schwartz, David A. , Shah, Jatin P. , John, Maie A. St. , Worden, Francis P. , Bruce, Justine Y. , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 12, 2025 | Volume: 23 | Issue: 2 | Pages: 2-11

10.6004/jnccn.2025.0007 | PMID 39938471 Get It

The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses, as well as occult primary cancer, salivary gland cancer, and mucosal melanoma (MM). The specific site of disease, stage, and pathologic findings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding management of nasopharynx cancer and ongoing research in this area.
Endoconduit: Utilizing the “Pave-and-Crack” Technique to Treat an Abdominal Aortic Aneurysm—A Contemporary Literature Review, and “How We Do It”
Garner, Sydney , Alsabbagh, Yaman , Sorrentino, Mariano, Dahiya, Rockey , Vandenberg, Jonathan , Mahajan, Biraaj, Farres, Houssam , Anderson, Erik , Fazzone, Brian , Jacobs, Christopher R. , Dahiya, Rockey , Sorrentino, Mariano, Erben, Young , Anderson, Erik , Filiberto, Amanda C. , Jacobs, Christopher

Mayo Clinic

Journal of Vascular Diseases | February 12, 2025 | Volume: 4 | Issue: 1 | Pages: 6

10.3390/jvd4010006 Get It

We present an 81-year-old male with an extensive past medical history and an enlarging abdominal aortic aneurysm (AAA). Axial imaging showed dense aortoiliac calcification with a complete occlusion of the right common iliac and high-grade stenosis of the left common iliac artery (CIA). Shockwave Intravascular Lithotripsy and the pave-and-crack technique utilizing an endoconduit were used to dilate the left external iliac artery and the CIA to facilitate placement of an aortic stent graft and exclude the patient’s AAA. This method gives surgeons the ability to treat patients with AAAs endovascularly, despite a heavily diseased and/or diminutive iliac anatomy. We also present a contemporary literature review of the utilization of the pave-and-crack technique as well as tips and tricks of how we do it.
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)
Pazo-Cid, Roberto , Chandana, Sreenivasa R , Dean, Andrew, Leei, Woo Jin, Goetze, Thorsten Oliver , Paulson, Andrew Scott , Bekaii‐Saab, Tanios , Pant, Shubham , Hubner, Richard , Xiao, Zhimin , Chen, Huanyu , Benzaghou, Fawzi, Bekaii-Saab, Tanios S , Wainberg, Zev A. , Melisi, Davide , Macarulla, Teresa , Fouchardière, Christelle de la , Kišš, Igor , Cutsem, Eric Van , Pant, Shubham , O’Reilly, Eileen M.

Mayo Clinic

Future Oncology | February 12, 2025 | Volume: 21 | Issue: 7 | Pages: 765-774

10.1080/14796694.2025.2458458 | PMID 39935331 Get It

Symposia Report of The Annual Biological Sciences Section Meeting of the Gerontological Society of America 2023, Tampa, Florida
Rogina, Blanka , Anderson, Rozalyn M. , Curan, Sean, Yousefzadeh, Matthew J. , Ghosh, Bhaswati, Duque, Gustavo , Howlett, Susan E. , Austad, Steven N. , Korfhage, Justin , Christensen, Kaare , Carey, James R. , Bell, Justice, Gomes, Ana P. , Dixit, Vishwa Deep , Sen, Payel , Imai, Shin‐ichiro , Valdez, Gregorio , Orr, Miranda E. , Jones, Leanne , Castillo-Azofeida, David, Bonaguidi, Michael A. , Suh, Yousin , Duncan, Francesca E. , C, Weigler G Perry, Burkewitz, Kristopher , Zhou, Kai , Bouhrara, Mustapha , Kolind, Shannon , Dean, Doug, Pálovics, Róbert , Niedernhofer, Laura J. , Fan, Rong , Bueckle, Andreas , Kapahi, Pankaj , Jiang, Nisi , Diaz, Jose , Mishra, Sidharth P. , Ralmundo, Nuno, Banarjee, Reema , Allsopp, Richard , Curran, Sean P. , Anderson, Rozalyn M , Curran, Sean P , Yousefzadeh, Matthew J , Duque, Gustavo , Howlett, Susan , Austad, Steven , Demuth, Ilja , Gerstorf, Denis , Abadir, Peter , Christensen, Kaare , Palmer, Allyson, Basisty, Nathan , de Cabo, Rafael , Sen, Payel , Baur, Joseph A , Duncan, Francesca E , Benjamini, Dan , Walker, Keenan A , Dean, Douglas C , Gladyshev, Vadim N , Fan, Rong , Sato, Shogo , Jiang, Nisi , Ashiqueali, Sarah A., Allsopp, Richard , Niedernhofer, Laura J , Kollind, Shannon H , LeBrasseur, Nathan K. , Lombard, David B. , Alberts, Susan C. , Campos, Fernando A. , Palavicini, Juan Pablo , Palmer, Allyson K. , Basisty, Nathan , Cabo, Rafael de , Baur, Joseph A. , Li, Xiaoling , Pletcher, Scott D. , Andersen, Julie Kay , Jones, Leanne, Suh, Yousin , Murray, Anna , Wang, Meng C., Henne, W. Mike , Walker, Keenan A. , Reiter, David A. , Gorbunova, Vera , Gladyshev, Vadim N. , Hurley, Jennifer , Esser, Karyn A. , Ashiqueali, Sarah , Reynolds, Lindsay M. , Zhang, Bohan , Sebastiani, Paola , Monti, Stefano , Schork, Nicholas J. , Rappaport, Noa

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | February 11, 2025 | Volume: 80 | Issue: 5 | Pages: No page available

10.1093/gerona/glaf026 | PMID 39932386 Get It

Abstract The aging process is universal, and it is characterized by a progressive deterioration and decrease in physiological function leading to decline on the organismal level. Nevertheless, a number of genetic and nongenetic interventions have been described, which successfully extend healthspan and lifespan in different species. Furthermore, a number of clinical trials have been evaluating the feasibility of different interventions to promote human health. The goal of the annual Biological Sciences Section of the Gerontological Society of America meeting was to share current knowledge of different topics in aging research and provide a vision of the future of aging research. The meeting gathered international experts in diverse areas of aging research including basic biology, demography, and clinical and translational studies. Specific topics included metabolism, inflammaging, epigenetic clocks, frailty, senescence, neuroscience, stem cells, reproductive aging, inter-organelle crosstalk, comparative transcriptomics of longevity, circadian clock, metabolomics, and biodemography.
Anatomy Insights and Key Pearls for Bronchial Artery Embolization
Cohen, E. , Schroeder, James W. , Habibollahi, Peiman , Ukeh, Ifechi, Özen, Merve , Anderson, Eric , Mansur, Arian , Ghadery, Abdolkarim Haji , Schroeder, Jamie Lee T., Boas, Franz Edward , Nezami, Nariman

Mayo Clinic

Seminars in Interventional Radiology | February 10, 2025 | Volume: 42 | Issue: 02 | Pages: 144-155

10.1055/s-0045-1802647 | PMID 40376216 Get It

AbstractAlthough bronchial artery embolization (BAE) initially emerged as a critical minimally invasive image-guided procedure to manage massive hemoptysis regardless of underlying etiologies, there has been a growing interest in BAE to treat pulmonary malignancies within recent years. This article provides an in-depth exploration of bronchial artery anatomy, pathologies, imaging modalities in guiding effective BAE, and procedural pearls for successful intervention. The complexity of bronchial artery anatomy, including its variations and potential complications during embolization, necessitates thorough understanding and precise procedural techniques to optimize patient outcomes and minimize risks.